

# Most Cost-Effective Setting Program Drug List

Established in 2012, the Most Cost-Effective Setting (MCES) Program requires that Independence Blue Cross (IBX) approve the treatment setting for certain medications eligible for coverage under the IBX medical benefit.

The main goal of the MCES Program is to manage the total cost of care by ensuring that plan members meet the coverage criteria in our medical policy, and that the requested treatment setting for these plan members is both safe and cost-effective. This review is conducted as part of the precertification process for plan members.

Drug	Date Added
Actemra® IV	September 1, 2017
Adakveo®	February 1, 2020
Adzynma	July 1, 2024
Amvuttra	July 1, 2022
Aralast NP®	July 1, 2012
Asceniv™	January 1, 2012*
Avsola™	February 1, 2020
Avtozma®	January 1, 2026
Benlysta® IV	June 1, 2018
Bildyos®	January 1, 2026
Bivigam®	January 1, 2012*
Bkemv™	January 1, 2025
Bosaya®	January 1, 2026
Briumvi®	July 1, 2024
Cerezyme®	January 1, 2012
Cinqair®	July 1, 2020
Conexence®	July 1, 2025
Crysvita®	October 1, 2018
Cutaquig®	January 1, 2012*
Cuvitru™	January 1, 2012*
ElELYso™	July 1, 2012
Elfabio®	January 28, 2024
Enjaymo™	July 1, 2022
Enoby	January 1, 2026
Entyvio®	September 1, 2017
Epysqli™	January 1, 2025
Evenity®	July 1, 2019
Evkeeza®	April 1, 2021
Fabrazyme®	July 1, 2012
Flebogamma®	January 1, 2012*
Flebogamma® DIF	January 1, 2012*
Fylnetra™	July 1, 2022
Gamastan® S/D	January 1, 2012*

Drug	Date Added
Gamifant®	November 20, 2018
Gammagard® Liquid	January 1, 2012*
Gammagard® S/D	January 1, 2012*
Gammaked™	January 1, 2012*
Gammaflex®	January 1, 2012*
Gamunex® C	January 1, 2012*
Givlaari™	February 1, 2020
Glassia®	July 1, 2012
Hizentra®	January 1, 2012*
HyQvia®	January 1, 2012*
Ilaris®	January 1, 2019
Ilumya™	November 1, 2018
Imaavy®	January 1, 2026
Imuldosa®	May 1, 2026
Inflectra®	September 1, 2017
infiximab (unbranded)	February 15, 2022
Ixifi™	June 1, 2018
Kanuma®	November 1, 2018
Lamzede	January 28, 2024
Lanreotide	December 1, 2022
Lapelga™	January 28, 2024
Leqvio®	February 15, 2022
Loargys®	May 1, 2026
Lumizyme®	July 1, 2012
Naglazyme®	October 1, 2018
Neupogen®	January 1, 2022
Nexviazyme™	September 15, 2021
Ocrevus™	January 1, 2018
Ocrevus Zunovo™	January 1, 2025
Octagam®	January 1, 2012*
Omyclo	July 1, 2025
Omvoh™	January 28, 2024
Onpattro™	August 10, 2018

Drug	Date Added
Orencia® IV	September 1, 2017
Ospomyv™	July 1, 2025
Oxlumo™	January 1, 2021
Panzyga®	January 1, 2012*
Pombiliti™	January 28, 2024
Privigen®	January 1, 2012*
Prolastin®	July 1, 2012
Prolia®	July 1, 2013
Qivigy®	January 1, 2026
Reblozyl®	February 1, 2020
Releuko™	July 1, 2022
Remicade®	September 1, 2017
Renflexis®	September 1, 2017
Revcovi™	November 1, 2018
Rolvedon®	December 1, 2022
Rystiggo®	January 28, 2024
Rytelo™	January 1, 2025
Ryzneuta™	January 28, 2024
Sandostatin® LAR depot	January 1, 2017
Saphnelo™	September 15, 2021
Selarsdi™	July 1, 2024
Simponi Aria®	September 1, 2017
Skyrizi® IV	December 1, 2022
Soliris®	January 1, 2012
Somatuline® depot	January 1, 2018
Spevigo®	December 1, 2022
Starjemza®	January 1, 2026
Stelara® IV	July 1, 2013
Stimufend®	December 1, 2022

Drug	Date Added
Tepezza®	April 1, 2021
Tofidence	January 28, 2024
Tremfya® IV	January 1, 2025
Tyenne®	July 1, 2024
Tyruko®	January 28, 2024
Tysabri®	September 1, 2019
Tzield®	December 1, 2022
Udenyca™	November 2, 2018
Udenyca Onbody™	July 1, 2024
Ultomiris™	December 21, 2018
Uplizna™	October 1, 2020
Veopoz™	July 1, 2024
Vimizim®	August 1, 2014
VPRIV®	January 1, 2012
Vyepti™	July 1, 2020
Vyvgart™	February 15, 2022
Wezlana™	January 28, 2024
Xbryk™	July 1, 2025
Xembify®	January 1, 2012*
Xolair®	July 1, 2013
Yesintek™	July 1, 2025
Yimmugo	January 1, 2025
Zemaira®	July 1, 2012
Ziextenzo®	February 1, 2020

This list is subject to change. All generics and biosimilars to a reference product in this program are subject to precertification review for most cost-effective setting.

\* The intravenous/subcutaneous immunoglobulin (IVIG/SCIG) class of drugs was added to the Most Cost-Effective Setting Program on January 1, 2012. Some drugs in this class were approved by the U.S. Food and Drug Administration after this date, but they reflect the January 1, 2012 date to indicate when program requirements went into effect for all drugs in that class.

# MCES Immunotherapy Expansion

On May 1, 2026, IBX launched our Immunotherapy MCES Expansion. Similar to the standard MCES list, the main goal of the addition of the below listed oncology drugs is to manage the total cost of care by ensuring that plan members meet the coverage criteria in our medical policy, and that the requested treatment setting for these plan members is both safe and cost-effective.

Members whose treatment fit any of the following criteria below will continue to receive care in the outpatient setting:

- Receiving a provider-administered combo chemotherapy at the same visit
- Less than 18 years of age
- Within the first 3 doses of starting therapy
- Experiencing severe toxicity requiring continuous monitoring (e.g. myocarditis, pericarditis, arrhythmias, impaired ventricular function, etc.)

Drug	Date Added
Darzalex/Faspro®	May 1, 2026
Imfinzi®	May 1, 2026
Jemperli®	May 1, 2026
Keytruda/Qlex®	May 1, 2026
Libtayo®	May 1, 2026
Loqtorzi®	May 1, 2026
Opdivo/Qvantig®	May 1, 2026
Rybrevant®/Faspro	May 1, 2026
Tecentriq®/Hybreza	May 1, 2026
Zynyz®	May 1, 2026

This list is subject to change. All generics and biosimilars to a reference product in this program are subject to precertification review for most cost-effective setting.

